News Sentiment

IPSC sentiment intelligence

Century Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.25 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-7.4% over one week, +0.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -7.4% Price reacting lower
Trend fit Trend active 0.0% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 43
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 9
TradingView 6
Investing.com 4
simplywall.st 4
Seeking Alpha 2
Investing News Network 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 14
Balance sheet 2
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Stock Titan Direct company coverage

Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24

Century Therapeutics (IPSC) director Lee Han Myung was granted 74,000 stock options with an exercise price of $2.24, expiring on June 11, 2036. The options will vest on the earlier of June 11, 2027, or the company's next annual meeting, provided Lee Han Myung continues his servic

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell

Century Therapeutics (IPSC) has granted its director, Kimberly Blackwell, a stock option award for 74,000 shares of common stock. These options have an exercise price of $2.24 per share and are set to expire on June 11, 2036. The shares will vest on the earlier of June 11, 2027,

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options

Century Therapeutics (IPSC) director Alessandro Riva was granted 74,000 stock options as compensation, allowing him to purchase common stock at an exercise price of $2.24 per share. These options expire on June 11, 2036, and will vest on the earlier of June 11, 2027, or the next

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate

Century Therapeutics (IPSC) stockholders approved an increase in authorized common shares from 300,000,000 to 450,000,000, effective June 12, 2026. At the same annual meeting, shareholders elected Alessandro Riva and Han Lee as Class II directors, serving until the 2029 Annual Me

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan
Zacks Investment Research Direct company coverage

Century Therapeutics (IPSC)

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2021 01:51
Source
Zacks Investment Research